BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1096 related articles for article (PubMed ID: 18852562)

  • 1. Neurofibrillary degeneration in Alzheimer's disease: from molecular mechanisms to identification of drug targets.
    Pei JJ; Sjögren M; Winblad B
    Curr Opin Psychiatry; 2008 Nov; 21(6):555-61. PubMed ID: 18852562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular dissection of the neurofibrillary lesions of Alzheimer's disease.
    Goedert M
    Arzneimittelforschung; 1995 Mar; 45(3A):403-9. PubMed ID: 7763334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of glycogen synthase kinase-3 in Alzheimer's disease pathogenesis and glycogen synthase kinase-3 inhibitors.
    Avila J; Wandosell F; Hernández F
    Expert Rev Neurother; 2010 May; 10(5):703-10. PubMed ID: 20420491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons.
    Padmanabhan J; Levy M; Dickson DW; Potter H
    Brain; 2006 Nov; 129(Pt 11):3020-34. PubMed ID: 16987932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration.
    Ferrer I; Barrachina M; Puig B
    Acta Neuropathol; 2002 Dec; 104(6):583-91. PubMed ID: 12410379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GSK-3 inhibitors for Alzheimer's disease.
    Avila J; Hernández F
    Expert Rev Neurother; 2007 Nov; 7(11):1527-33. PubMed ID: 17997701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.
    Hardy J; Selkoe DJ
    Science; 2002 Jul; 297(5580):353-6. PubMed ID: 12130773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Neurofibrillary tangles and early modification of the neuronal cytoskeleton in Alzheimer's disease and in experimental models].
    Brion JP
    Bull Mem Acad R Med Belg; 1999; 154(6 Pt 2):287-94. PubMed ID: 10992876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration.
    Wang JZ; Xia YY; Grundke-Iqbal I; Iqbal K
    J Alzheimers Dis; 2013; 33 Suppl 1():S123-39. PubMed ID: 22710920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Truncated tau from sporadic Alzheimer's disease suffices to drive neurofibrillary degeneration in vivo.
    Zilka N; Filipcik P; Koson P; Fialova L; Skrabana R; Zilkova M; Rolkova G; Kontsekova E; Novak M
    FEBS Lett; 2006 Jun; 580(15):3582-8. PubMed ID: 16753151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An aluminum-based rat model for Alzheimer's disease exhibits oxidative damage, inhibition of PP2A activity, hyperphosphorylated tau, and granulovacuolar degeneration.
    Walton JR
    J Inorg Biochem; 2007 Sep; 101(9):1275-84. PubMed ID: 17662457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of neurofibrillary tangles in Alzheimer disease.
    Brion JP
    Acta Neurol Belg; 1998 Jun; 98(2):165-74. PubMed ID: 9686275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ultrastructural aspects of neurofibrillary tangle formation in aging and Alzheimer's disease.
    Gómez-Ramos P; Morán MA
    Microsc Res Tech; 1998 Oct; 43(1):49-58. PubMed ID: 9829459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-tau based neuronal degeneration in Alzheimer's disease -- an immunocytochemical and quantitative study in the supragranular layers of the middle temporal neocortex.
    van de Nes JA; Nafe R; Schlote W
    Brain Res; 2008 Jun; 1213():152-65. PubMed ID: 18455153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal by desferrioxamine of tau protein aggregates following two days of treatment in aluminum-induced neurofibrillary degeneration in rabbit: implications for clinical trials in Alzheimer's disease.
    Savory J; Huang Y; Wills MR; Herman MM
    Neurotoxicology; 1998 Apr; 19(2):209-14. PubMed ID: 9553957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of protein kinase B in Alzheimer's neurofibrillary pathology.
    Pei JJ; Khatoon S; An WL; Nordlinder M; Tanaka T; Braak H; Tsujio I; Takeda M; Alafuzoff I; Winblad B; Cowburn RF; Grundke-Iqbal I; Iqbal K
    Acta Neuropathol; 2003 Apr; 105(4):381-92. PubMed ID: 12624792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transgenic zebrafish model of neurodegeneration.
    Tomasiewicz HG; Flaherty DB; Soria JP; Wood JG
    J Neurosci Res; 2002 Dec; 70(6):734-45. PubMed ID: 12444595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease.
    Buerger K; Ewers M; Pirttilä T; Zinkowski R; Alafuzoff I; Teipel SJ; DeBernardis J; Kerkman D; McCulloch C; Soininen H; Hampel H
    Brain; 2006 Nov; 129(Pt 11):3035-41. PubMed ID: 17012293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration.
    Wang JZ; Grundke-Iqbal I; Iqbal K
    Eur J Neurosci; 2007 Jan; 25(1):59-68. PubMed ID: 17241267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Up-regulation of cell division cycle (cdc) 2 kinase in neurons with early stage Alzheimer's disease neurofibrillary degeneration.
    Pei JJ; Braak H; Gong CX; Grundke-Iqbal I; Iqbal K; Winblad B; Cowburn RF
    Acta Neuropathol; 2002 Oct; 104(4):369-76. PubMed ID: 12200623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 55.